DICE Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | — | $1.1M | $863,000 |
| Operating income | −$88.2M | −$47.6M | −$23.7M |
| Net income | −$83.9M | −$49.0M | −$23.7M |
| Total assets | $594.0M | $325.8M | $63.9M |
| Total liabilities | $27.0M | $12.8M | $9.6M |
| Equity | $567.0M | $312.9M | −$53.1M |
| EPS (diluted) | $-2.13 | $-3.95 | — |
| Shares out. | 38.2M | 12.4M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −14.8%
- Return on assets
- −14.1%
- Return on capital (ROCE)
- −15.2%
- Liabilities / assets
- 4.5%
- Debt / equity
- 0.05×
- Book value / share
- $14.83
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 26.24safe
- Accruals / assets
- −3.3%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 9, 2023
- Entered a material agreement · Other material eventJun 20, 2023
- Amended charter or bylaws · Shareholder voteJun 7, 2023
- Results of operationsMay 11, 2023
- Results of operationsMar 15, 2023
- Director / officer changeFeb 10, 2023
- Amended charter or bylawsNov 17, 2022
- Results of operationsNov 9, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GAug 21, 2023
- EFFECTAug 10, 2023
- 4OWNERSHIP DOCUMENTAug 9, 2023
- SC 13D/AAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- 4FORM 4 SUBMISSIONAug 9, 2023
- S-8 POSAug 9, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.